Pazopanib
- PDF / 138,889 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 152 Views
1
S
Neutropenia and various other toxicities: case report A 47-year-old man developed severe neutropenia and various other toxicities during treatment with pazopanib for CNS haemangioblastoma. The man presented with treatment-refractory haemangioblastoma in 2006, and had been diagnosed with von Hippel-Lindau (VHL) disease at the age of 16 years. Renal cell carcinoma (RCC) was also diagnosed in 2008. He commenced treatment with sunitinib, but treatment was stopped due to severe neutropenia and poor therapeutic response; his neutrophil counts subsequently normalised. In February 2010, pazopanib 800 mg/day [route not stated]. He experienced mild adverse reactions including transient diarrhoea, fatigue, hypertension and oral mucosal ulcerations. He also developed neutropenia, with a neutrophil count of 0.87 K/µL. Amlodipine was prescribed, with good BP control. At last follow-up, the man remained moderately neutropenic. Pazopanib was continued at the same dosage. Author comment: "With the exception of his development of severe neutropenia, our patient experienced only mild adverse events (grades 1 and 2). Mild hypertension, fatigue, oral mucosal ulcerations, and diarrhea were the main nonhematological toxicities in our patient." Kim BYS, et al. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease. Targeted Oncology 7: 145-149, No. 2, Jun 2012. Available 803079349 from: URL: http://dx.doi.org/10.1007/s11523-012-0214-0 - USA
0114-9954/10/1426-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 3 Nov 2012 No. 1426
Data Loading...
